Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatment.
Siegel AN, Rodrigues N, Nasri F, Wilkialis L, Lipsitz O, Lee Y, Gill H, Subramaniapillai M, Phan L, Majeed A, Lui LMW, Rashidian H, Ho R, Toma S, Goldstein BI, Mansur RB, McIntyre RS, Rosenblat JD. Siegel AN, et al. Among authors: lipsitz o. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jan 10;104:110032. doi: 10.1016/j.pnpbp.2020.110032. Epub 2020 Jul 4. Prog Neuropsychopharmacol Biol Psychiatry. 2021. PMID: 32634540 Review.
The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS, Rodrigues NB, Lipsitz O, Nasri F, Gill H, Lui LM, Subramaniapillai M, Kratiuk K, Teopiz K, Ho R, Lee Y, Mansur RB, Rosenblat JD. McIntyre RS, et al. Among authors: lipsitz o. J Psychopharmacol. 2021 Feb;35(2):128-136. doi: 10.1177/0269881120954048. Epub 2020 Oct 11. J Psychopharmacol. 2021. PMID: 33040665
The Prevalence of Suicidal Behaviour in Fibromyalgia Patients.
Gill H, Perez CD, Gill B, El-Halabi S, Lee Y, Lipsitz O, Park C, Mansur RB, Rodrigues NB, McIntyre RS, Rosenblat JD. Gill H, et al. Among authors: lipsitz o. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jun 8;108:110078. doi: 10.1016/j.pnpbp.2020.110078. Epub 2020 Aug 24. Prog Neuropsychopharmacol Biol Psychiatry. 2021. PMID: 32853715
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis.
McIntyre RS, Carvalho IP, Lui LMW, Majeed A, Masand PS, Gill H, Rodrigues NB, Lipsitz O, Coles AC, Lee Y, Tamura JK, Iacobucci M, Phan L, Nasri F, Singhal N, Wong ER, Subramaniapillai M, Mansur R, Ho R, Lam RW, Rosenblat JD. McIntyre RS, et al. Among authors: lipsitz o. J Affect Disord. 2020 Nov 1;276:576-584. doi: 10.1016/j.jad.2020.06.050. Epub 2020 Jul 21. J Affect Disord. 2020. PMID: 32871689 Review.
Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O, McIntyre RS, Rodrigues NB, Kaster TS, Cha DS, Brietzke E, Gill H, Nasri F, Lin K, Subramaniapillai M, Kratiuk K, Teopiz K, Lui LMW, Lee Y, Ho R, Shekotikhina M, Mansur RB, Rosenblat JD. Lipsitz O, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 8;105:110126. doi: 10.1016/j.pnpbp.2020.110126. Epub 2020 Oct 5. Prog Neuropsychopharmacol Biol Psychiatry. 2021. PMID: 33031861
Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment.
Ng J, Lui LMW, Rosenblat JD, Teopiz KM, Lipsitz O, Cha DS, Xiong J, Nasri F, Lee Y, Kratiuk K, Rodrigues NB, Gill H, Subramaniapillai M, Mansur RB, Ho R, Cao B, McIntyre RS. Ng J, et al. Among authors: lipsitz o. Psychopharmacology (Berl). 2021 Apr;238(4):917-926. doi: 10.1007/s00213-021-05767-1. Epub 2021 Jan 23. Psychopharmacology (Berl). 2021. PMID: 33484298 Review.
The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE).
McIntyre RS, Rosenblat JD, Rodrigues NB, Lipsitz O, Chen-Li D, Lee JG, Nasri F, Subramaniapillai M, Kratiuk K, Wang A, Gill H, Mansur RB, Ho R, Lin K, Lee Y. McIntyre RS, et al. Among authors: lipsitz o. Psychiatry Res. 2021 Aug;302:113993. doi: 10.1016/j.psychres.2021.113993. Epub 2021 May 13. Psychiatry Res. 2021. PMID: 34034067
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders.
Ceban F, Rosenblat JD, Kratiuk K, Lee Y, Rodrigues NB, Gill H, Subramaniapillai M, Nasri F, Lui LMW, Lipsitz O, Kumar A, Lee JG, Chau EH, Cao B, Lin K, Ho RC, Mansur RB, Swainson J, McIntyre RS. Ceban F, et al. Among authors: lipsitz o. CNS Drugs. 2021 Sep;35(9):925-934. doi: 10.1007/s40263-021-00846-5. Epub 2021 Aug 7. CNS Drugs. 2021. PMID: 34363603 Review.
Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects.
Le TT, Di Vincenzo JD, Teopiz KM, Lee Y, Cha DS, Lui LMW, Rodrigues NB, Ho RC, Cao B, Lin K, Nasri F, Gill H, Lipsitz O, Subramaniapillai M, Mansur RB, Rosenblat JD, McIntyre RS. Le TT, et al. Among authors: lipsitz o. Psychiatry Res. 2021 Dec;306:114231. doi: 10.1016/j.psychres.2021.114231. Epub 2021 Oct 9. Psychiatry Res. 2021. PMID: 34798487 Review.
50 results